SynthesisJBRA assisted reproduction2026
Comparative Outcomes of Letrozole Versus Clomiphene Citrate for Ovulation Induction in Patients With PCOS: Systematic Review and Meta-Analysis.
Synthesis in JBRA assisted reproduction, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dominant Follicle Size as a Predictor of Pregnancy in Letrozole Intrauterine Insemination.Journal of clinical medicine · 2026Article
- Effect of Letrozole Administration on Reproductive Performance and Plasma Metabolites of Ewes During Estrus Synchronization Treatment.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to synthesize available high-quality randomized controlled trials (RCTs) comparing reproductive outcomes between letrozole (LE) and clomiphene citrate (CC) for ovulation induction in women with PCOS.
methodsFollowing PRISMA guidelines, this review was registered in PROSPERO (CRD420251013416). A comprehensive search was conducted in PubMed, Cochrane Library, Elsevier, the National Library of Medicine, and Google Scholar up to March 2025. A total of 32 RCTs were included. Statistical analysis used a random-effects model to calculate risk ratios (RR) with 95% confidence intervals (CI), as determined using Review Manager. Heterogeneity was assessed with the I2 statistic. The risk of bias was evaluated using the ROB 2 tool. The primary outcome was ovulation rate; secondary outcomes included pregnancy, live birth, miscarriage, and multiple pregnancy rates.
resultsLE showed higher ovulation (RR: 1.18; 95% CI: 1.11-1.25; I2: 57%) and pregnancy rates (RR: 1.57; 95% CI: 1.39-1.76; I2: 21%) compared to CC. LE also had a higher live birth rate (RR: 1.54; 95% CI: 1.24-1.91; I2: 35%). Miscarriage rates were similar between groups (RR: 0.97; 95% CI: 0.73-1.28; I2: 0%). The multiple pregnancy rate was significantly lower in the LE group (RR: 0.42; 95% CI: 0.18-0.98; I2: 0%).
conclusionsLetrozole shows greater effectiveness than clomiphene citrate for ovulation induction in women with PCOS, with a lower risk of multiple pregnancy and similar miscarriage risk. These findings support its use as a first-line treatment in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.